Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner

Blood

Volumn 92, Issue 5, 1998, Pages 1497-1504

  Wang, Zhu Gang ^b   Rivi, Roberta ^b   Delva, Laurent ^b   König, Andrea ^b   Scheinberg, David A ^b   Gambacorti Passerini, Carlo ^b   Gabrilove, Janice L ^a   Warrell Jr , Raymond P ^b   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; HYBRID PROTEIN; MELARSOPROL; PROTEIN BCL 2; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL;

EID: 0032170898     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1497     Document Type: Article

References (30)

1. Schamberg JF, Kolmer JA, Brown H: Arsenoxide in relation to the toxicity and therapeutic activity of arsphenamine and neoarsphenamine. Am J Syph Neurol 18:37,1934
2. Kuzoe FAS: Current situation of African trypanosomiasis. Acta Trop 54:153, 1993
3. Forkner C, McNair-Scott TF: Arsenic as a therapeutic agent in chronic myeloid leukemia. JAMA 97:305, 1931
4. Sun HD, Ma L, Hu XC, Zhang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 12:170, 1992
5. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
6. 3) in acute promyelocytic leukemia. Proc Am Soc Clin Oncol 17:6a, 1998
7. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6:1285, 1991
8. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66:663, 1991
9. de Thè H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML/RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
10. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaube MP, Chambon P, Pelicci PG: Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemia. EMBO J 11:1397, 1992
11. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88:1052, 1996
12. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H: Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978, 1997
13. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARa protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124, 1998
14. Look AT: Arsenic and Apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst 90:86, 1998
15. König A, Wrazel L, Warrell RP Jr, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90:562, 1997
16. Pandolfi PP, Rivi R, Gaboli M, Giorgio M, Antoniou M, Bygrave A, Fagioli M, Cordon-Cardo C, Pelicci PG, Luzzatto L, Grosveld F: Targeted disruption of the PML gene of acute promyelocytic leukemia. Blood 86:261a, 1995 (abstr, suppl 1)
17. Wang ZG, Giorgio M, Rivi R, Cordon-Cardo C, Gaboli M, Pandolfi PP: Growth and tumor suppressive properties of the PML gene of acute promyelocytic leukemia in PML-/- mice. Blood 88:477a, 1996 (abstr, suppl 1)
18. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP: Role of PML in cell growth and the retinoic acid pathway. Science 297:1547, 1998
19. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992
20. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, Pelicci PG, Nervi C: Retinoid-induced differentation of acute promyelocytic leukemia involves PML-RARα-mediated increase of type II transglutaminase. Blood 87:1939, 1996
21. Bouteille M, Lavai M, Dupuy-Coin AM: Localization of nuclear functions as revealed by ultrastructural autoradiography and cytochemistry, in Busch H (ed): The Cell Nucleus. New York, NY, Academic, 1974, p 5
22. Ascoli C, Maul GJ: Identification of a novel nuclear domain. J Cell Biol 112:785, 1991
23. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
24. Dyck J, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333, 1994
25. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RARalpha in acute promyelocytic leukemic cells. Cell 76:345, 1994
26. Yang CH, Wang TY, Chen YC: Cytotoxcity of arsenic trioxide in cancer cell lines. Proc Am Assoc Cancer Res 39:227, 1998
27. Calleja E, Konig A, Warrell RP Jr, Gabrilove JL: Arsenic trioxide induces apoptosis in K562 chronic myelogenous leukemia (CML) cells. Blood 90:3636, 1997 (abstr, suppl 1)
28. Calleja E, Gabrilove JL, Warrell RP Jr: Arsenic trioxide inhibits cell survival in a variety of cancer cell types. Proc Am Soc Clin Oncol 17:218a, 1998
29. Soignet SL, Rivi R, Konig A, Tong WP, Gabrilove JL, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Melarsoprol, an organic arsenical, in the treatment of refractory leukemia: Laboratory and clinical results. Blood 90:507a, 1997 (abstr, suppl 1)
30. Westervelt P, Pollock J, Huag J, Ley TJ, DiPersio JF: Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia. Blood 90:3859a, 1997 (abstr, suppl 1)